GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study

In ASCVD patients with BMI ≥30 kg/m2 on statins, adding a GLP-1 receptor agonist is linked to lower all-cause mortality (4.0% vs 7.5%; HR 0.479).

• Why it matters: It addresses whether GLP-1 RA therapy provides cardiovascular outcome advantages beyond statin monotherapy in obese ASCVD patients.
• What they did: Using TriNetX data from 108 U.S. healthcare organizations, investigators propensity score–matched 166,278 GLP-1 RA initiators to 920,176 statin-only controls on 34 covariates, then followed 119,911 matched pairs for 3 years.
• The result: GLP-1 RA use was associated with lower MI (HR 0.762) and ischemic stroke (HR 0.671), with consistent findings in BMI ≥35 and washout sensitivity analyses.

AI summary of the abstract · may contain errors · not medical advice · read the paper.